TUESDAY, March 29, 2016 (HealthDay News) -- Participants with a negative low-dose computed tomography (CT) prevalence screen (T0) have lower incidence of lung cancer and lung cancer-specific mortality than all participants with a T0 screen, according to a study published online March 18 in The Lancet Oncology.
Edward F. Patz, Jr., M.D., from the Duke University Medical Center in Durham, N.C., and colleagues conducted a retrospective cohort analysis of data from the National Lung Screening Trial in high-risk eligible adults. The cohort included 26,231 participants assigned to the low-dose CT screening group who had undergone their T0 screen.
The researchers found that, compared with all 26,231 T0-screen participants, the 19,066 participants with a negative T0 screen had a lower incidence of lung cancer (371.88 versus 661.23 per 100,000 person-years) and had lower lung cancer-related mortality (185.82 versus 277.20 per 100,000 person-years). Among participants with a negative T0 screen, the yield of lung cancer at the first annual screen (T1) was 0.34 percent, compared with a yield of 1 percent at the T0 screen among all T0-screened participants. An additional 28 participants in the T0-negative group would have died from lung cancer over the course of the trial if the T1 screen had not been done in the T0-negative group.
"Because overly frequent screening has associated harms, increasing the interval between screens in participants with a negative low-dose CT prevalence screen might be warranted," the authors write.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
